The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | The effect of t(11;14) on the efficacy of venetoclax in myeloma: data from a retrospective analysis
Harsh Parmar, MD, Hackensack University Medical Center, Hackensack, NJ, comments on the role of venetoclax in the treatment of multiple myeloma (MM), highlighting the effect of the t(11;14) translocation on the efficacy of this agent. Dr Parmar notes that patients harboring the t(11;14) translocation exhibit a higher response rate and prolonged progression-free survival (PFS) compared to those without it, emphasizing the importance of identifying this subgroup to inform treatment selection. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So GPRC5D has emerged as a new therapeutic target for patients with relapsed multiple myeloma. And we are heading towards a paradigm where a biomarker-driven therapeutic strategy is very important. So we assessed samples from 280 patients with multiple myeloma, and what we found was that there was a lot of difference in terms of mRNA expression for GPRC5D as well as SLAMF7, but not so much when it comes to BCMA and CD138...
So GPRC5D has emerged as a new therapeutic target for patients with relapsed multiple myeloma. And we are heading towards a paradigm where a biomarker-driven therapeutic strategy is very important. So we assessed samples from 280 patients with multiple myeloma, and what we found was that there was a lot of difference in terms of mRNA expression for GPRC5D as well as SLAMF7, but not so much when it comes to BCMA and CD138. And we found that the levels of mRNA expression were different between patients when it came to GPRC5D, and this also correlated with the expression of SLAMF7. And this can have an impact in terms of treatment for patients with multiple myeloma because about 3% of patients did not have any GPRC5D expression.
So the outcome yet needs to be determined. More studies need to be undertaken. Theoretically speaking, if you do not have GPRC5D expression, there will be compromised efficacy when it comes to therapies that target GPRC5D, and you would experience inferior outcomes for patients who have low levels of GPRC5D expression compared to those who have a higher level of expression. So that remains to be seen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
